| Today’s Big NewsNov 13, 2023 |
| By James Waldron Novartis is going to give a solid-tumor-focused cell therapy the T-Charge treatment after paying $100 million upfront to Legend Biosciences for a selection of CAR-T candidates. |
|
|
|
By Nick Paul Taylor Verve Therapeutics has published the first data on an in vivo base editing program in humans, giving the world an early look at the effects of a cholesterol-busting candidate that could become part of Eli Lilly’s stable of heart disease drugs. But investors pummeled the stock amid potential safety concerns. |
By Max Bayer A day after AstraZeneca inked a new $185 million licensing deal to reenter the GLP-1 frenzy, CEO Pascal Soriot says the future marketplace will center less on treating obesity and more on sustained weight management. |
Sponsored by Questex Fierce Biotech sits down with digital marketing leaders to discuss this year's most innovative topics at Fierce Biotech Summit and New Product Planning |
|
Reduce sequence artifacts that dampen variant calling sensitivity. Prepare highly complex libraries in under 1.5 hours, and minimize damage and loss with precious low-input and FFPE material. Learn more. 
|
|
By Max Bayer Selecta is reverse merging with Cartesian to bolster its cash coffers and add a lifeline in a difficult public market. The focus of the new venture will be Cartesian's cell therapy aimed at autoimmune diseases. |
By Nick Paul Taylor Midphase data are arriving thick and fast at Imbria Pharmaceuticals. Days after sharing positive top-line data in one indication, the cardiometabolic biotech has reported a phase 2 trial of the same candidate in a different setting has met its primary endpoint. |
By Gabrielle Masson VectorY Therapeutics has secured €129 million ($138 million) in a series A financing that will help the Dutch biotech advance its preclinical lead program in ALS. |
By James Waldron Aclaris Therapeutics has abandoned its immuno-inflammatory plans for zunsemetinib after the latest phase 2 fail saw the MK2 inhibitor unable to match placebo on any primary or secondary endpoints in a rheumatoid arthritis trial. |
By James Waldron Only two and a half years after Pfizer acquired infectious disease biotech Amplyx for an undisclosed sum, the Big Pharma has sold the lead antifungal asset from that deal to Basilea Pharmaceutica. |
By Angus Liu A few months ago, Fierce Pharma asked employees working in the biopharma industry to use photographs to tell their stories during the pandemic. Now, we’re showcasing those precious memories here. |
By Conor Hale No, you didn’t set your clocks too far back. This week, the FDA granted its first full, bona fide clearance to an over-the-counter home antigen test for COVID-19, after hundreds of emergency authorizations. |
By Ben Adams Madrigal Pharmaceuticals has hired Carole Huntsman as its new chief commercial officer to help the biotech navigate a new and potentially tricky launch in NASH. |
By Andrea Park In a world-first procedure earlier this year, a vast team of surgeons and OR staff at NYU Langone Health successfully performed a whole-eye and partial-face transplant on a man who had survived a high-voltage electrical accident, the hospital announced this week. |
By Nick Paul Taylor GSK is building its presence in the myelofibrosis community. Working with interior designer and former "Queer Eye" star Thom Filicia, the Big Pharma is launching the Mapping Myelofibrosis health education initiative to support patients with the blood cancer treated by its recently approved drug Ojjaara. |
By Anastassia Gliadkovskaya Nearly two-thirds of specialty centers that conduct autism evaluations have wait times longer than four months, according to a new report. |
Fierce podcasts Don’t miss an episode |
| In this episode of “The Top Line,” we explore the next potential wave of mental health therapy: psychedelics. |
|
|---|
|
|
Webinar Watch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Download our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
Whitepaper This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| Edison Ballroom, New York City |
|
|
| |
|
